High efficiency intranasal drug delivery using Intravail® alkylsaccharide absorption enhancers

Drug Delivery and Translational Research

Volumn 3, Issue 1, 2013, Pages 16-25

  Maggio, Edward T ^a   Pillion, Dennis J ^b  

^a Aegis Therapeutics LLC   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Alkylsaccharide; Drug delivery; Intranasal; Intravail ; Peptide; Polysorbate; Protein aggregation

Indexed keywords

ALKYL GROUP; ALKYLSACCHARIDE; BETA INTERFERON; CALCITONIN; DIAZEPAM; EXCIPIENT; INSULIN; UNCLASSIFIED DRUG;

BIOAVAILABILITY; DRUG ABSORPTION; DRUG FORMULATION; HUMAN; INTRANASAL DRUG ADMINISTRATION; MOLECULAR MECHANICS; MOLECULAR WEIGHT; PRIORITY JOURNAL; REVIEW;

EID: 84875227166     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-012-0069-z     Document Type: Review

References (48)

1. Hussain AA. Intranasal drug delivery. Adv Drug Deliv Rev. 1998; 29: 39-49.
2. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000; 11: 1-18.
3. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Rel. 2003; 87: 187-98.
4. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol. 2004; 56: 3-17.
5. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and therapeutic aspects. Intl J Pharm. 2007; 337: 1-24.
6. Pontiroli AE. Peptide hormones: review of current and emerging uses by nasal delivery. Adv Drug Deliv Rev. 1998; 29: 81-7.
7. Sayani AP, Chien YW. Systemic delivery of peptides and proteins across absorptive mucosae. Crit Rev Ther Drug Carrier Syst. 1996; 13: 85-184.
8. Song Y, Wang Y, Thakur R, Meidan VM, Michniak B. Mucosal drug delivery: membranes, methodologies, and applications. Crit Rev Ther Drug Carrier Syst. 2004; 21: 195-256.
9. Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc LJ, Le Guen M, Fischler M, Devillier P. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther. 2012; 134(3): 366-79.
10. Pires A, Fortunal A, Alves G, Falcão A. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci. 2009; 12(3): 288-311.
11. Material Safety Data Sheet TEGOSOFT LSE 65 K SOFT Evonik Goldschmidt GmbH Version: 1. 11 Date Issued: 01/21/2010 Goldschmidtstr. 100 Essen, 05 45127.
12. Kocher K, Wiegand HJ. Toxicology and dermatology. In: Balzer D, editor. Surfactant science series, Vol. 91, Non ionic surfactants: alkylpolyglucosides. New York: Marcel Dekker; 2000. p. 365-83.
13. Sucrose esters of fatty acids and sucroglycerides (WHO Food Additives Series 40), The forty-ninth meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA) Geneva 1998. http://www. inchem. org/documents/jecfa/jecmono/v040je04. htm.
14. Gizurarson S, Gudbrandsson FK, Jónsson H, Bechgaard E. Intranasal administration of diazepam aiming at the treatment of acute seizures: clinical trials in healthy volunteers. Biol Pharm Bull. 1999; 22(4): 425-7.
15. Rifkin RA, Maggio ET, Dike S, Kerr DA, Levy M. n-Dodecyl-β-d-maltoside inhibits aggregation of human interferon-β-1b and reduces its immunogenicity. J Neuroimmune Pharmacol. 2011; 6: 158-62.
16. Maggio ET. Use of excipients to control aggregation in peptide and protein formulations. J Excip Food Chem. 2010; 1: 40-9.
17. Federal Register: September 14, 2005 (Volume 70, Number 177)] Page 54281-54286 Alkyl (C10-C16) Polyglycosides; exemptions from the requirement of a tolerance.
18. Ha E, Wei Wang W, Wang YJ. Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci. 2002; 91: 2252-64.
19. Hamburger R, Azaz E, Donbrow M. Autoxidation of polyethylenic non-ionic surfactants and of polyethylene glycols. Pharm Acta Helv. 1975; 50: 10-7.
20. Jaeger J, Sorensen K, Wolff SP. Peroxide accumulation in detergents. J Biochem Biophys Methods. 1994; 29: 77-81.
21. Lam XM, Lai WG, Chan EK, Ling V, Hsu CC. Site-specific tryptophan oxidation induced by autocatalytic reaction of polysorbate 20 in protein formulation. Pharm Res. 2011; 28: 2543-55.
22. Chen S-C, Eiting KT, Li AAW, Lamharz N. and Quay SC. Peptide drug permeation enhancement by select classes of lipids. 45th American Society for Cell Biology Meeting, December 10-14, 2005, San Francisco (late abstract).
23. Scotto-Lavino E, Easow J, Simon S, Roemer E. An in vitro model for the rapid screening of potential components and formulations for nasal drug delivery. In Vitro Cell Dev Biol. 2002; 38: 12A.
24. El-Shafy MA, Roemer E, de Meireles J, Biswas M, Quay SC. Permeability and cytotoxicity of macromolecules from nasal formulations using EpiAirway™ tissue model. AAPS Pharm Sci. 2001; 3(3): S-58.
25. Chen S-C, Eiting KT, Li AAW, Lamharz N, Quay SC. Identification of tight junction modulating lipids. J Pharm Sci. 2009; 98(2): 606-19.
26. Arnold JJ, Ahsan F, Meezan E, Pillion DJ. Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells. J Pharm Sci. 2004; 93(9): 2205-13.
27. Cüreoǧlu S, Akkus M, Osma U, Yaldiz M, Oktay F, Can B, Güven C, Teki{dotless}n M, Meri{dotless}ç F. The effect of benzalkonium chloride on rabbit nasal mucosa in vivo: an electron microscopy study. Eur Arch Otorhinolaryngol. 2002; 259: 362-4.
28. Arnold JJ, Fyrberg MD, Meezan E, Pillion DJ. Reestablishment of the nasal permeability barrier to several peptides following exposure to the absorption enhancer tetradecyl-b-d-maltoside. J Pharm Sci. 2010; 99(4): 1912-20.
29. Ahsan F, Arnold J, Meezan E, Pillion DJ. Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats. Pharm Res. 2001; 18(12): 1742-6.
30. Illum L. Nasal delivery. The use of animal models to predict performance in man. J Drug Target. 1996; 3(6): 427-42.
31. Maggio ET, Meezan E, Ghambeer DKS, Pillion DJ. High bioavailability formulation of salmon calcitonin-potential opportunities for expanded use in analgesia. Drug Deliv Technol. 2010; 10: 58-63.
32. Krause D, Eddy P, Merutka G, MacDonald B. Intranasal (IN), pharmacokinetic (PK) and bioavailability of ZT-034 a parathyroid hormone (PTH) analog. ASBMR Poster Presentation Number: SU0405 September 13, 2009.
33. Eddy P, Krause D, Merutka G, MacDonald B. Intranasal (IN) pharmacokinetics (PK) and bioavailability of ZT-031, a novel parathyroid hormone (PTH) analog. ASBMR Poster Presentation Number: MO0385 September 14, 2009.
34. Neurelis announces positive results from phase 1 pharmacokinetic study of NRL-01 (intranasal diazepam) http://www. bizjournals. com/prnewswire/press_releases/2011/06/14/LA19174. Accessed 15April 2012.
35. Ivaturi VD, Riss JR, Kriel RL, Cloyd JC. Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. Acta Neurol Scand. 2009; 120(5): 353-7.
36. Ivaturi VD, Riss JR, Kriel RL, Siegel RA, Cloyd JC. Bioavailability and tolerability of intranasal diazepam in healthy adult volunteers. Epilepsy Res. 2009; 84(2-3): 120-6.
37. Li L, Nandi I, Kim KH. Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam. Int J Pharm. 2002; 237(1-2): 77-85.
38. Maggio ET. Compositions for drug administration. US Patent Application 2010/0160378A1, June 24, 2010.
39. Waldrop MA, Grasso P. Intranasal delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin like activity, improves energy balance, glycemic control, insulin sensitivity, and bone formation in leptin-resistant C57BLK/6-m db/db mice. Diabetes, Obes Metab. 2010; 12: 871-5.
40. Novakovic ZM, Leinung MC, Lee DW, Grasso P. Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. Regul Pept. 2009; 154: 107-11.
41. Maggio ET. Intranasal administration of active agents to the central nervous system. US Pat App. 2011/0129462A1, June 2, 2011.
42. Lee DW, Leinung MC, Grasso P. OB3 Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice: a study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administration. Regul Pept. 2010; 160: 129-32.
43. Novakovic ZM, Leinung MC, Lee DW, Grasso P. Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J wild-type and ob/ob mice: effects on energy balance, glycemic control and serum osteocalcin levels. Diabetes, Obes Metab. 2010; 12: 532-9.
44. Maggio ET, Grasso P. Oral delivery of octreotide acetate in Intravail improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss Webster mice. Regul Pept. 2011; 167: 233-8.
45. Leinung MC, Grasso P. [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide (Byetta®) and pramlintide (Symlin®) on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice. Regulatory Peptides. 2012; in press.
46. Bennett JA, DeFreest L, Anaka I, Saadati H, Balulad S, Jacobson HI, Andersen TT. AFPep: an anti-breast cancer peptide that is orally active. Breast Cancer Res Treat. 2006; 98: 133-41.
47. Andersen TT, Georgekutty J, DeFreest LA, Amaratunga G, Narendran A, Lemanski N, Jacobson HI, Bennett JA. An α-fetoprotein-derived peptide reduces the uterine hyperplasia and increases the antitumour effect of tamoxifen. Br J Cancer. 2007; 97: 327-33.
48. DeFreest LA, Mesfin FB, Joseph L, McLeod DJ, Stallmer A, Reddy S, Balulad SS, Jacobson HI, Andersen TT, Bennett JA. Synthetic peptide derived from alpha-fetoprotein inhibits growth of human breast cancer: investigation of the pharmacophore and synthesis optimization. J Pept Res. 2004; 63(5): 409-19.